Payment overview · 2025
General Payments
$1,589.90
71 reported records · 13 companies
Healthcare provider profile · identity verified
Nirali Ritesh Parikh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GLENDALE HEIGHTS, IL · NPI 1831374172
Verified facts
What the public records show
CMS Open Payments records show Nirali Ritesh Parikh, M.D. received $1,589.90 in general payments during 2025 across 71 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $328.50 | 20.7% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $249.65 | 15.7% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $244.19 | 15.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.15 | 12.0% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $169.88 | 10.7% | 8 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $98.72 | 6.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.26 | 4.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.86 | 3.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.67 | 2.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.66 | 2.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.94 | 2.8% | 2 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $21.32 | 1.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.10 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,589.90 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $244.19 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $233.25 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $218.10 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $196.46 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $118.77 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $102.75 | 5 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $98.72 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $88.40 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $83.85 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.26 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.86 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.06 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.66 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.66 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 149 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 233 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
149 | 36 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 61 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1009 | 286 |
| Levothyroxine Sodium | Levothyroxine Sodium | 645 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 163 |
| Losartan Potassium | Losartan Potassium | 548 | 140 |
| Metformin Hcl | Metformin Hcl | 532 | 150 |
| Lisinopril | Lisinopril | 359 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 335 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 104 |
| Fluticasone Propionate | Fluticasone Propionate | 236 | 117 |
| Jardiance | Empagliflozin | 233 | 61 |
| Alendronate Sodium | Alendronate Sodium | 219 | 65 |
| Azithromycin | Azithromycin | 201 | 161 |
| Carvedilol | Carvedilol | 185 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 48 |
| Januvia | Sitagliptin Phosphate | 176 | 39 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 169 | 64 |
| Simvastatin | Simvastatin | 164 | 43 |
| Gabapentin | Gabapentin | 154 | 52 |
| Omeprazole | Omeprazole | 154 | 48 |
| Farxiga | Dapagliflozin Propanediol | 149 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 44 |
| Glimepiride | Glimepiride | 133 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 33 |
| Montelukast Sodium | Montelukast Sodium | 130 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 126 | 73 |
| Alprazolam | Alprazolam | 125 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 39 |
| Furosemide | Furosemide | 117 | 42 |
| Glipizide | Glipizide | 111 | 31 |
| Methylprednisolone | Methylprednisolone | 94 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 34 |
| Atenolol | Atenolol | 86 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 26 |
| Tramadol Hcl | Tramadol Hcl | 77 | 37 |
| Eliquis | Apixaban | 76 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 20 |
| Ozempic | Semaglutide | 71 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 55 |
| Cephalexin | Cephalexin | 65 | 42 |
| Famotidine | Famotidine | 65 | 24 |
| Hydrocortisone | Hydrocortisone | 64 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 16 |
| Sertraline Hcl | Sertraline Hcl | 57 | 12 |
| Allopurinol | Allopurinol | 53 | 16 |
| Ezetimibe | Ezetimibe | 51 | 19 |
| Metformin Hcl Er | Metformin Hcl | 51 | 14 |
| Spironolactone | Spironolactone | 51 | 14 |
| Finasteride | Finasteride | 49 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 29 |
| Meloxicam | Meloxicam | 42 | 20 |
| Potassium Chloride | Potassium Chloride | 40 | 13 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 32 | 11 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 26 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ofloxacin | Ofloxacin | 24 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Prednisone | Prednisone | 19 | 12 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Prolia | Denosumab | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,589.90 · 71 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OFEV, OTEZLA, Ozempic, REPATHA, SPRAVATO, VOQUEZNA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error